<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1572">
  <stage>Registered</stage>
  <submitdate>22/12/2003</submitdate>
  <approvaldate>22/12/2003</approvaldate>
  <actrnumber>ACTRN12607000041459</actrnumber>
  <trial_identification>
    <studytitle>Efficacy study of adding chemotherapy to radiotherapy for treating bladder cancer</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 02.03 - Multicentre Phase III study comparing Radical Synchronous Chemo-Radiation (cisplatin) vs Radical Radiation Alone in the Definitive Management of Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder Following Maximal Trans-Urethral Resection to reduce invasive local failure.</scientifictitle>
    <utrn />
    <trialacronym>TROG 02.03</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00330499</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR476</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Transitional Cell Carcinoma of Urinary bladder</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ARM A: Synchronous chemo/radiation therapy. Weekly infusional cisplatin 35mg/m sqaured x 6 doses plus radiation 64Gy/32 fractions over 6 1/2 weeks.</interventions>
    <comparator>ARM B: Radiation alone. 64Gy/32 fractions over 6 1/2 weeks.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Invasive local failure</outcome>
      <timepoint>At 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Complete response rate</outcome>
      <timepoint>At 3mths from randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Disease free survival.</outcome>
      <timepoint>Time from randomisation to failure or death. Measured until death.  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Overall survival.</outcome>
      <timepoint>Time from randomisation to death from any cause. Measured unitl death.  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Acute and late toxicity.</outcome>
      <timepoint>Measured every 3 months for the first yr, 6 monthly until 3 yrs and then yearly until death.  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Pattern of failure. Local failure, regioanl failure, distant failure and death are anaylsed.</outcome>
      <timepoint>Measured every 3 months for the first yr, 6 monthly until 3 yrs and then yearly until death.  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. Quality of Life measures.</outcome>
      <timepoint>Measured pre treatment, week 7 at the end of treatment, 3mths, 12 months post treatment and 2 years post treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologically proven Transitional Cell Carcinoma (TCC) of the urinary bladder. Mixed tumours comprising predominantly TCC and elements of squamous or adenomatous metaplasia or carcinoma are also eligible.
2. Clinically and radiologically localised T2, T3 or T4a non-bulky disease (&lt;= 7cm in maximum dimension), N0, M0.If radiological evaluation of a lymph node is interpreted as positive this must be evaluated further by either lymph node sampling or percutaneous needle biopsy. Patients with histologically confirmed lymph node metastases will not be eligible. 
3. Maximal Trans Urethral Resection (TUR). N.B. Previous: a) partial cystectomy; b) endoscopic resection of bladder tumour/s; c) intravesical chemotherapy; or d) intravesical Bacillus Calmette-Guerin (BCG)
does not exclude the patient from being eligible. However, the patient should have an adequate functioning bladder (this should be clarified with the referring Urologist and if need be voiding volumes should be measured). 
4. Creatinine clearance &gt;= 50ml/minute by calculation or measurement.
5. A white blood cell count &gt;= 3.5 x 109/L with an absolute neutrophil count &gt;= 1.5 x 109/L and a platelet count &gt;= 100 x 109/L
6. Eastern Cooperative Oncology Group status of 0, 1 or 2.
7. No age limit applies provided the patient is mentally, physically and geographically capable of undergoing treatment and follow-up.
8. No significant intercurrent morbidity.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pure squamous carcinomas or adenocarcinomas.
2. Extensive or multifocal Carcinoma In Situ (CIS) change in the bladder.
3. T3 or T4a tumours unsuitable for curative treatment (i.e. &gt; 7cm in any dimension), T4b, node positive and metastatic disease.
4. Presence of ureteric obstruction due to tumour infiltration at the Ureteral Orifice (UO) not amenable to stenting.
5. Previous radiation treatment to the pelvis.
6. Previous significant pelvic surgery.
7. Significant bowel or gynaecological inflammatory disease.
8. Creatinine clearance &lt; 50ml/minute by calculation or measurement. A white blood cell count &lt; 3.5 x 109/L with an absolute neutrophil count &lt; 1.5 x 109L and/or a platelet count &lt; 100 x 109/L.
9. Other considerations making patient unfit for Cisplatin therapy.
10. Prior or concurrent malignancy of any other site unless disease-free for greater than 5 years, except for:1. non-melanoma skin cancer, and/or 2. a) Stage T1 well differentiated prostatic carcinoma in men, and b) In situ carcinoma of the cervix in women.
11. Bladder tumour  biopsy only. These patients must be referred back for more adequate resections or else should not be included.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation</concealment>
    <sequence>Stratified allocation. Factors: Stage T2/T3/T4a, Complete Trans Urethral resection only, Centre. Simple randomisation by computer.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>11/10/2002</anticipatedstartdate>
    <actualstartdate>11/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate>11/11/2007</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>67</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>9/02/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Kumar Gogna</primarysponsorname>
    <primarysponsoraddress>Mater QRI Raymond Terrace SOUTH BRISBANE QLD 4101</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council Project Grant</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Edith St Waratah NSW 2298</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Radiation and chemotherapy both work in people with muscle-invasive bladder cancer.  This study will determine if giving them together improves the results for people with this disease that seems to be confined to the bladder, but who are felt to be suitable candidates for bladder preserving treatment.</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication>Abstract 65:  Gogna K. TROG 02.03: Intergroup Phase III Randomised Study, Chemotherapy vs radiation alone: Compliance, Toxicity, Quality of Life and overall results. Poster presentation ASCO May 30-June 2, 2014, Chicago Illinois.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>William Buckland radiotherapy Centre, The Alfred</ethicname>
      <ethicaddress>Prahran, VIC</ethicaddress>
      <ethicapprovaldate>31/05/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress>Auckland, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Campbelltown Hospital</ethicname>
      <ethicaddress>Campbelltown, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Christchurch, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress>Dunedin, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Premion Tugun</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Andrew Love Cancer centre, Geelong Hospital</ethicname>
      <ethicaddress>Geelong, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston Hospital</ethicname>
      <ethicaddress>Launceston, TAS</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress>Liverpool, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Hospital</ethicname>
      <ethicaddress>Penrith, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Palmerston North</ethicname>
      <ethicaddress>Papaioea, Manawatu-Wanganui, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress>Randwick, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>Adelaide, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Herston, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Perth, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>Nedlands, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress>Wellington, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworthville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Kumar Gogna</name>
      <address>Mater QRI
Raymond Terrace
SOUTH BRISBANE QLD 4101</address>
      <phone>+61 7 3840 3255</phone>
      <fax />
      <email>Kumar_Gogna@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Kacy Baumann</name>
      <address>Mater QRI
Raymond Terrace
South Brisbane QLD 4101</address>
      <phone>+61 7 3840 3219</phone>
      <fax />
      <email>Kacy_Baumann@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rebecca Montgomery</name>
      <address>TROG Cancer Research
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3910</phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kumar Gogna</name>
      <address>Queensland Radium Institute-Mater Centre
Raymond Terrace
South Brisbane, Queensland, 4101, Australia
</address>
      <phone>+61 7 3840 3255</phone>
      <fax />
      <email>Kumar.Gogna@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>